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Peter Socrates Creticos1,2Abstract
Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy
that offer the potential to suppress the IgE-mediated allergic disease process through induction of T-cell tolerance.
These synthetic T-cell-tolerizing peptides have been designed to induce immunologic tolerance via binding to MHC
class II molecules on antigen presenting cells, with subsequent upregulation of regulatory T-cells.Introduction
Specific allergen immunotherapy (AIT) is employed to
attenuate or tolerize the immune response to specific al-
lergens and is recommended for patients in whom allergic
rhinitis symptoms cannot be controlled by medication and
environmental control, or in patients that cannot tolerate
their medications, or in patients that are non-compliant
with chronic medication regimens [1,2].
AIT has been shown to reduce the immediate phase of
clinical reactivity (mast cell mediator release), inhibit
cellular recruitment (eosinophils; basophils) in the late
phase, and resolve the underlying inflammatory process
that characterizes allergic rhinitis. The mechanisms by
which this is accomplished continue to be investigated,
but are currently thought to include a reduction of
allergen-specific Th2 T-cell responses mediated by in-
creased Th1 or regulatory T cell responses to the same
allergen [3,4].
Conventional subcutaneous (SCIT) injection regimens
employ increasing doses of the allergen extract, adminis-
tered once or twice weekly, as tolerated, until the patient
reaches a predetermined “maintenance” dose (e.g. 6–12 μg
Amb a 1 (2000–4000 BAU)/injection). The optimal dur-
ation of SCIT with a licensed allergen extract is not well
defined; but, general recommendations are to administer
the maintenance dose one or twice monthly over 3–5
years [1,2]. However, this approach is not optimal, as it
is limited by the potential for systemic allergic reactions,
including anaphylaxis, it utilizes a tedious long-termCorrespondence: psocrates@comcast.net
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unless otherwise stated.treatment regimen that negatively impacts upon patient
compliance, and in some patients it is only partially effect-
ive. Hence, there is a need for newer therapeutic agents
that can be administered more easily (either fewer injec-
tions or a different route of immunization), are safer (have
a reduced risk of serious adverse reactions), and can pro-
vide effective benefit to a larger percentage of patients.
Through the years, various chemical modifications of
allergen have been attempted to enhance efficacy, im-
prove safety, and foster compliance with AIT. Recent ap-
proaches with modified allergens, adjuvants, including
immune-stimulatory adjuvants, recombinant allergens,
T-cell tolerizing constructs, and improved oral approaches
have been demonstrated in various clinical studies to pro-
vide measurable benefit in treatment of allergic respiratory
disease [5-9].
Synthetic T-cell-tolerizing peptides
Studies carried out by Gefter and colleagues, and other
investigators, in the mid-1990s provided the first evidence
that synthetic T-cell-tolerizing peptides could induce
tolerance and thereby be used to suppress IgE-mediated
diseases such as cat and ragweed-induced rhinitis and
asthma. His lab developed both cat (two 27 amino acid
peptides derived from Fel d 1) and ragweed T-cell-
tolerizing peptides and in collaborative studies with
Norman, Creticos et al. demonstrated that various treat-
ment regimens, in which the peptides were adminis-
tered subcutaneously, provided significant improvement
in cat-induced clinical symptoms in the cat studies (cat
room challenges; cat broncho-provocation studies), and
of allergic rhinoconjunctivitis symptoms in multicenter
trials of a ragweed vaccine. Furthermore, the peptidesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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suggesting immune tolerance [10-15].
However, these first-generation peptides were longer
sequences, fewer in number, and given subcutaneously
at much higher doses; in clinical trials, they suffered
from a late-onset adverse event profile, and a therapeutic
result that was less than optimal when contrasted to
conventional SCIT. Development of this approach was
halted in the late-1990s.
New promising research into peptide epitopes initiated
at Imperial College by Larché and Kay has resulted in a
second generation of these molecules with the subsequent
development of Synthetic Peptide Immuno-Regulatory
Epitopes (SPIREs). These synthetic T-cell-tolerizing
peptides are comprised of smaller peptide units (e.g.:
cat: seven peptides; 13–17 amino acids in length), ad-
ministered in much smaller quantities (75 μg vs.
750 μg), are assembled from different T-cell epitopes
and are administered intradermally to access antigen
presenting cells [16-22].
These novel peptides are designed to induce immuno-
logic tolerance via binding to MHC class II molecules on
antigen presenting cells, with subsequent up-regulation of
regulatory T-cells. A key advantage of the peptides lies in
their smaller size; i.e., molecules that are of insufficient
length to trigger cross-linking of IgE on mast cells and ba-
sophils, may provide an advantage by potentially reducing
the risk of IgE-mediated allergic reactions such as asthma,
urticaria, or anaphylaxis [16-22].
Cat-SPIRE
Cat-SPIRE development
Cat-SPIRE [Circassia Ltd.; Oxford, U.K.] consists of 7
separate small peptides (13–17 AA in length) derived
from Fel d 1, the major cat allergenic moiety. It is pre-
pared as a lyophilisatea and must first be reconstituted
in sterile water for intradermal injection into the dermis
[21,23] (a see Endnotes).
The selection of peptides in Cat SPIRE were pre-defined
based on MHC class II binding studies using appropriate
cell lines and upon conducting T-cell proliferation and
histamine release assays on ex-vivo blood samples from
cat allergic human volunteers in order to identify the
specific T-cell epitopes of interest. T-cell proliferative
responses to cat dander allergen extract and Cat-SPIRE
correlated closely and provided confirmatory evidence
that the majority of T cell reactivity to cat dander could
be ascribed to the specific epitopes contained within
Cat-SPIRE. As importantly, the cytokine responses against
whole cat dander and Cat-SPIRE showed a skewing to-
ward a T-regulatory IL-10 protective response [19,21,23].
Furthermore, as important as the identification and se-
lection of the appropriate T-cell epitopes for Cat-SPIRE,
the assessment and determination of the compound’sIgE-binding activity was equally critical to the design of
the therapeutic agent. Basophil histamine release assays
on whole blood from cat-allergic individuals affirmed
that Cat-SPIRE possessed significantly less potential than
whole allergen to cross-link IgE thereby reducing the po-
tential to cause either local injection reactions or systemic
reactions [16-23].
A synthetic mixture of T cell epitopes (Cat SPIRE)
capable of being administered in a short 4-injection
treatment regimen, with a more practical intradermal
method of application (as opposed to a subcutaneous
injection), affords a therapeutic construct that offers a
significant improvement to the method of administra-
tion of immunotherapy - one that has the potential to
positively impact upon patient compliance. The animal
and human investigational studies to date have provided
promising evidence to support that long-lasting clinical
benefit can be achieved with this approach [24].Animal studies
An initial mechanistic study by Campbell et al. in trans-
genic mice demonstrated that treatment with a specific
cat peptide (one of the peptides in Cat-SPIRE) resulted in
reductions in BAL (bronchoalveolar lavage) total cells and
eosinophils (cells indicative of allergic inflammation), re-
ductions in pulmonary and systemic TH2 inflammatory
cytokines, reduced recruitment of TH2 cells to the lungs,
and reduced proliferative responses to Fel d 1 [19].
Administration of an anti-IL-10 monoclonal antibody
immediately after treatment with the peptide blocked
these positive peptide-induced effects and provided im-
munologic evidence that IL-10 is a critical cytokine in the
underlying mechanism of action ascribed to SPIREs for
re-establishment of immune tolerance.
Although this is an artificial acute sensitization animal
model, its findings are consistent with the current un-
derstanding of the role of regulatory T-cells in allergen
immunotherapy. Furthermore, the parallel observations
that mixtures of peptides from Cat-SPIRE induced in-vitro
IL-10 release from peripheral blood mononuclear cells
(PBMCs) from >90% of cat-allergic subjects provides
additional evidence for the ability of the peptide con-
struct to induce clinical tolerance [19].Clinical studies
Phase I/IIa safety and efficacy study
Worm et al. published their initial safety and efficacy
findings on Fel d 1 peptide immunotherapy in 2011 [21].
Cat-SPIRE was administered in a double-blind, placebo-
controlled clinical trial which employed an escalating
single-dose intradermal (ID) or subcutaneous (SQ) injec-
tions to evaluate safety and efficacy in 88 cat allergic
subjects [21].
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the primary surrogate efficacy endpoint was defined as
the change in mean diameter of the LPSR (late phase
skin response) vs. placebo at 8-hours post-ID challenge
with whole cat allergen on Day 21 after receipt of Cat-
SPIRE or placebo. That is a well-recognized clinical end-
point to assess the effect of immunotherapy in allergic
subjects. It was determined that the greatest inhibition
of the LPSR response to ID whole allergen challenge was
observed with the 3 nmol dose (~37.5 mcg of Fel d 1
peptides). This dose resulted in approximately a 40% re-
duction in the LPSR vs. 10% for placebo. This change
did not achieve statistical significance, which given the
small number of subjects involved is not unexpected.
However, the positive trend combined with the antibody
data helped to define the subsequent treatment dose for
future development [21].
Cat-SPIRE was well-tolerated in doses up to 12 nmol
(given ID) and 20 nmol (given SQ), as well as no clinically
significant changes in any laboratory parameter, abnormal-
ities on ECG testing, or adverse findings on physical exam
were observed. No serious adverse events (SAEs) were ob-
served during the study, and no subject withdrew from
the study due to an adverse event. The most common
treatment-emergent adverse events in the ID-immunized
subjects were nasopharyngitis, cough, and headache;
whereas, in the SQ-immunized subjects, nasal conges-
tion and respiratory symptoms were reported - not unlike
what might be observed with SCIT (subcutaneous in-
jection immunotherapy) to whole cat extract [21].
Furthermore, no subjects in the ID-immunized cohort
exhibited a reduction in FEV1 greater that 20% from base-
line (considered indicative of a meaningful asthmatic re-
sponse) and none reported any asthma-like symptoms
during the 8-hour post-dosing period [21,25].
In comparison to SCIT, it is recognized that the effect-
ive maintenance dose for immunotherapy is ~15 mcg of
Fel d 1, but that a buildup phase of approximately 4–6
months is required to achieve this dose level. Hence, the
findings that Cat-SPIRE was safe and well-tolerated at a
single dose of up to 12 nmol (ID) (equivalent to ~150
mcg of Fel d 1) provided initial confirmatory evidence
that Cat-SPIRE could be administered at an effective dose
that that might not necessitate a lengthy dose escalation
or buildup phase [1,2,21].
Phase II clinical study
The Environmental Exposure Chamber (EEC) provides a
controlled setting in which to evaluate drugs (e.g., anti-
histamines; nasal corticosteroids) and allergen immuno-
therapy. It provides a surrogate to field trials and avoids
many of the challenges associated with outdoor seasonal
(and perennial) immunotherapy studies (i.e., weather
changes; pollutant exposures; confounding aeroallergenexposure) that can affect phase II multi-center studies.
Furthermore, it is possible to expose patients to pre-
defined allergen levels that are “expected” to cause
symptoms of sufficient severity to allow assessment of
drug effect [26].
This model was chosen to perform dose-ranging studies
and to explore the dose-dependent clinical efficacy that
might be expected with Cat-SPIRE immunotherapy in cat-
allergic volunteers. In the EEC design, study subjects had
a baseline EEC visit consisting of 4 consecutive days on
which patients were exposed for three hours each day in
the chamber. The subjects were then re-exposed in the
EEC at 18–22 weeks after the start of treatment.
One-hundred and twenty-one (121) subjects who met
a qualifying threshold symptom score were randomized
to one of four treatment arms or placebo: a) 4 adminis-
trations of 3 nmol 2 weeks apart; b) 4 administrations of
6 nmol 2 weeks apart; c) 4 administrations of 3 nmol
4 weeks apart; d) 8 administrations of 3 nmol 2 weeks
apart; e) 8 administrations of placebo; all dosing regimens
included placebo infill injections where necessary to main-
tain the blind [27,28].
The primary endpoint (defined as the difference in TRSS
at each time point on each day between baseline and post-
treatment challenge (PTC) demonstrated a greater degree
of efficacy when the study subjects were dosed over 12–14
weeks as opposed to 6 weeks. Although not based on in-
tent to treat (ITT) analysis (due to technical issues) those
patients who attended the main study center and who re-
ceived the 8 administrations of 3 nmol 2 weeks apart dose
regimen reported a reduction of symptoms versus placebo
(p < .05). A trend was also observed for the 6 nmol dose to
be superior to the 3 nmol dose [27,28].
No serious adverse events were observed in this study
with any of the four treatment regimens. TEAEs in all
cohorts (except the 6 nmol cohort) were less than the
placebo cohort (the 6 nmol cohort trended slightly
higher). However, respiratory system TEAEs (including
asthma, dyspnea, and wheezing) occurred at a low fre-
quency in all groups, and no difference was observed
between active groups or placebo [27,28].
Recognizing that the goal of immunotherapy is to in-
duce a long-lasting treatment effect that is maintained
post-cessation of treatment, this EEC study provided
preliminary evidence that a sustained treatment effect
could be achieved with Cat-SPIRE. Obviously, the 18–
22 week findings were intriguing and led to additional
EEC work to establish duration of treatment effect –
that is the ability of a short course of immunotherapy
with Cat-SPIRE to induce a long-lasting disease-
modifying effect. The work by Durham et al. with SCIT
has demonstrated that a 3-year course of immunother-
apy with a modified standardized grass extract can in-
duce sustained benefit in the 2-years post-cessation of
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munotherapy constructs [29].
Phase IIb clinical study with 1-year follow-up
The focus of this study, by Patel and colleagues, was to
further define the persistence of treatment effect in
study patients with cat-induced AR undergoing treat-
ment with Cat-SPIRE [24].
This randomized, double-blind, placebo-controlled
study used the same baseline challenge methodology as
the earlier study (baseline challenge consisting of 4 con-
secutive days of 3 hours in the EEC) and had patients
undergo cat challenge in the EEC at 18–22 weeks and at
50–54 weeks after the start of treatment. The primary
endpoint was defined as the change in TRSS, (post-treat-
ment vs. baseline EEC challenges) at 1–3 hours on days
2–4. The Cat-SPIRE regimen randomized 202 patients
to either: a) 4 doses of 6-nmol 4 weeks apart (n = 66);
b) 8 administrations of 3 nmol 2 weeks apart (n = 67);
or c) placebo (n = 69) [24].
The results of this 1-year study demonstrated a per-
sistent treatment effect in the pre-specified statistical
analysis at time points after 1 hour on Days 2–4 of
EEC at the 50–54 week EEC challenge in the non-
asthmatic population for the 6 nmol × 4 dose regimen
vs. placebo (median change: -6.80 (vs. -3.27); mean
change: -3.89 +/-5.56 (vs. -2.91 +/-5.56); LS means:Day 1
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Figure 1 Delta changes in total rhinoconjunctivitis symptom scores fo
environmental exposure chamber.-7.074, -4.077; 95% CIs: -7.165 to -0.989; p value =0.0104).
Analysis of the data at all time points on all days showed
similar results [24].
Furthermore, the clinical effects were similar when
assessing “all patients” (including patients with asthma)
with the 6 nmol × 4 dose regimen vs. placebo (median
change: -6.03 (vs -3.20); mean change: -6.35 +/-5.75 (vs.
-2.49 +/-5.39); LS means: -6.507, -3.878; 95% CIs: -6.586
to -1.158; p value =0.0057). This finding demonstrates that
asthmatic subjects not only tolerate the immunization
regimen but likewise demonstrate a clinical benefit
that is sustained and similar to that seen in the cohort
with AR without asthma at the 1-year follow-up EEC
challenge [24].
Analyses on the secondary endpoints of nasal and ocular
symptoms, respectively, showed that similar benefit was
seen in both of these parameters at the 1-year time point
(total nasal symptom score (mean change): -3.44 +/- 3.05
(vs. -1.63 +/-2.95); p value vs. placebo =0.02 // total
ocular symptom score (mean change): -3.34 +/- 3.05
(vs. -1.28 +/- 2.92); p value vs. placebo =0.01) and high-
lights the prominence of ocular symptoms in cat-induced
AR [24].
Figure 1 displays the mean TRSS symptom scores at
each 30-minute time point in the chamber over the 4
consecutive exposure days for the baseline EEC chal-
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the treatment effect to be stronger on successive days in
the EEC [24].
The magnitude of change in TRSS scores for CAT-
SPIRE (~4 TRSS units) compares favorably with allergen
chamber studies of a SLIT cat allergy drops (change:
1.6u), or an antihistamine (change: 1.3u) in similar allergen
EEC studies [23,24].
Cat-SPIRE was reasonably well-tolerated. There was
one serious AE (skin laceration) in a subject in the pla-
cebo group. There were no SAEs in the asthmatic subset
of patients as related to their asthma. The majority of
TEAEs were mild in severity, and no TEAEs were rated
as severe. Six subjects did not complete the study because
of a TEAE (1 on placebo (back pain); 5 in Cat-SPIRE
groups: arthralgia and extremity pain (1 patient; 3 nmol);
bronchospasm (2 patients that received 3 nmol); hyper-
sensitivity (1 patient; 6 nmol); presyncope and convulsion
(1 patient; 6 nmol)). Of note, save the hypersensitivity re-
action (allergy symptoms self-medicated with an antihista-
mine and a cold medicine), the other 5 withdrawals due to
TEAEs were assessed as unrelated to study drug [24].
Analysis of respiratory system-related TEAES did not
elicit any untoward safety signal. There were no reduc-
tions in FEV1 of greater than 30%, (which was the pro-
spectively defined cutoff, as based on clinical experience
which provides a comfort level with bronchodilator re-
sponsiveness). Three subjects that received 6 nmol experi-
enced an episode of dyspnea, bronchospasm, or asthma;
whereas, 14 subjects that received 3 nmol and 11 subjects
that received placebo reported such an episode [24].
The findings from this study extend the observations
made in the earlier EEC clinical trial and provide evidence
that a consistent and long-lasting effect on symptoms
can be induced through immunization with Cat-SPIRE
in cat-allergic individuals. The well-defined EEC model
has proven to be a valuable tool in defining dose, determin-
ing treatment effect, and establishing clinical evidence for
sustained therapeutic efficacy that is consistent with find-
ing from animal models and in-vitro assays in cat-allergic
subjects treated with immune-modulating peptides.
Phase IIb clinical study - two-year follow-Up
Of the 86 patients that completed all visits at the 1-year
follow-up, 51 agreed to re-consent, remain blinded, and
enroll in the 2-year follow-up study. No further treatment
was administered [25,30]. Study subjects underwent repeat
chamber challenge at 102–106 weeks. As before, both
subjects and study staff remained blinded.
A sustained improvement in mean TRSS from baseline
was observed for the 6 nmol group (-5.87) as compared
to the 3 nmol group (-3.05) and the placebo group
(-2.02) at the post-treatment challenge (102–106 weeks
after the start of treatment) (LS mean treatment difference(for the 6 nmol) vs. placebo was -3.85 (95% CI: -8.83, 1.14;
p = 0.13). Although this trend did not reach significance
for the primary endpoint, a statistically significant differ-
ence in findings was observed for pre-specified secondary
endpoint when the cumulative allergen challenge was
greatest (Day 4, 3 hours) (p = .02). Furthermore, consistent
reductions in nasal symptoms (2–3 units) were observed
in the 6 nmol group compared to placebo at multiple time
points during the 4-day chamber exposure (e.g. the 2–3
hour time point in the EEC on days 1–4 (p = .05) [25,30].
The findings from this 2-year follow-up study provide
a degree of evidence that points to a persistence of effect,
albeit limited, even at 2 years post-completion of a short
course of immunization to Cat-SPIRE is encouraging.
This persistence of effect will need to be evaluated
further in larger studies.
Current phase III clinical field study
Recruitment for this clinical trial is underway in North
America and Europe. This clinical trial aims to provide
meaningful clinical data in a “real world” setting – that
is, cat allergic patients who live with cats in their home
environment.
This is a randomized, double-blind, placebo-controlled
clinical trial of adolescents and adults (ages: 12–65). It is
properly powered to include study subjects stratified
(based on asthma status and age) in a 1:1:1 ratio to ac-
tive therapy with either: a) 4 × 6 nmol of Cat-SPIRE
doses 4 weeks apart (followed by 4 injections of placebo
4 weeks apart); or b) 4 × 6 nmol of Cat-SPIRE doses
4 weeks apart (followed by a second course of Cat-
SPIRE 4 weeks apart); or c) placebo (two courses of 4
doses 4 weeks apart) [31].
The primary endpoint for this multi-center clinical
trial is the mean CS (Combined Score: TRSS + RMS
(Rhinoconjunctivitis Medication Score) during Weeks
52–54 after randomization in the Cat-SPIRE group com-
pared to the mean CS in the placebo-treated group. In
addition, multiple secondary endpoints of clinical effi-
cacy will be measured in the clinical field trial [31].
Other synthetic peptide immuno-regulatory epitope
constructs in development
Recent work with ragweed SPIRE [32] and house dust
mite SPIRE [33] have also provided initial evidence that
these constructs can be delivered safely and demonstrate
effect in skin, conjunctival, and/or environmental cham-
ber provocation models.
Conclusion
Synthetic peptides comprised of T-cell epitopes, whose
sequence is derived from known amino acid sequences
of specific allergens, provide a therapeutic approach
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lasting clinical efficacy.
Endnote
aStudy medication manufacture: The peptides were syn-
thesized by Bachem (Bubendorf, Switzerland), according to
current Good Manufacturing Practice. The lyophilized
Cat-PAD product was formulated, filled, and finished by
Patheon (Monza, Italy) and the lyophilized placebo was
manufactured by Aptuit (Glasgow, United Kingdom), also
according to current Good Manufacturing Practice. The ma-
terials were tested at Patheon and Gen-Probe (Livingston,
United Kingdom) and released in accordance with the
European Union (Directive 2001/20/EC) and Canadian
(Food and Drug Act, Section C.05.010) regulations after
labeling and packaging at Aptuit (Bathgate, United Kingdom).
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